Roche Applied Science Announces Winners of 454 Life Sciences' 10GB Grant Program
The two first-place winners will use the 10GB sequencing award to study African sleeping sickness drug resistance and ant fungal garden metagenomes
The 10GB winning project in Europe, led by Pascal Mäser from the Swiss Tropical Institute (formerly University of Bern), together with Harry de Koning from the University of Glasgow, will use the sequencing award to uncover low-frequency genetic mutations in the parasite species Trypanosoma brucei subspecies which causes African sleeping sickness. The disease occurs in Sub-Saharan Africa and is fatal if left untreated, a situation which is aggravated by the occurrence of drug-resistant strains. "We are excited about the opportunity to use the Genome Sequencer FLX System to identify the mutations underlying drug resistance in T. brucei subspecies," explained Mäser. "The data generated with the 10GB Grant Program will take us closer to developing DNA-based tests for the diagnostics of drug resistance in sleeping sickness."
The 10GB award in North America will support the sequencing efforts of the fungal garden ant project, led by Nicole Gerardo from Emory University, Cameron Currie from the University of Wisconsin, and George Weinstock from Washington University in St. Louis. For approximately 50 million years, leaf-cutting ants have been farming fungi for food. Like human agriculture, this ancient system is complex, involving symbiotic associations between farmers, crops, beneficial microbes and harmful pathogens.
"Building on previous ecological and evolutionary studies, we will utilize metagenomics, transcriptomics and genomics based on the Genome Sequencer FLX System to explore the molecular processes underlying these intimate associations," stated Nicole Gerardo. "While doing so, we will build an infrastructure to integrate community-based genome exploration with cross-disciplinary studies in genomics, molecular biology, developmental biology, ecology and evolution."
Runner-up winners include projects to sequence the Arctic ice metagenome, examine the evolution of the drosophila genome, and perform genomic analysis of the silver fox.
Open to all researchers globally, this year's grant program received a record number of registrants - a testament to the increasing impact of sequencing as a tool in nearly all fields of biology. "We are pleased to see the adoption of the Genome Sequencer FLX System across a wide range of scientific disciplines," said Chris McLeod, President and CEO of 454 Life Sciences, a Roche company. "While one winning team will use the sequencing to deepen our understanding of one of the oldest and most complex symbiotic relationships described in nature, another will use the technology towards possible treatment improvements for a fatal human disease in the future. We are inspired by the scientific community and their ability to find new applications for the Genome Sequencer FLX System."
454 Life Sciences, develops and commercializes the innovative Genome Sequencer FLX System for ultra-high-throughput DNA sequencing. Specific applications include de novo sequencing and re-sequencing of genomes, metagenomics, RNA analysis, and targeted sequencing of DNA regions of interest. The hallmarks of the Genome Sequencer FLX System are its simple, unbiased sample preparation and long, highly accurate sequence reads, including paired-end reads. The technology of the Genome Sequencer FLX System has enabled hundreds of peer-reviewed studies in diverse research fields, such as cancer and infectious disease research, drug discovery, marine biology, anthropology, paleontology, and many more.
About Roche Diagnostics Deutschland GmbH
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.
In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.